



ASX Announcement

18 April 2019

Creso Pharma Granted Licence to Import its First Medicinal Cannabis Product into Brazil

Highlights

- **Creso and its marketing partner SIN Solution have received regulatory clearance from Brazilian health regulatory agency ANVISA for the importation of Creso's medicinal cannabis product cannaQIX®50**
- **cannaQIX®50 is Creso's first medicinal cannabis product to be made available in Brazil**
- **The product will be sold through importation and distribution by MedDepot Brasil**
- **SIN Solution is providing marketing and doctors and patients with support to ensure smooth access to the Creso's product**
- **cannaQIX®50 aims to help patients with neuropathic and cancer-related pain**
- **SIN Solution has direct access to more than 350,000 health professionals and over 200,000 patients**

Creso Pharma Limited (ASX:CPH) (the "Company" or "Creso"), is pleased to announce that it has received approval to import its first medicinal cannabis product into Brazil.

Creso and its marketing partner, SIN Solution, have received regulatory clearance from Brazilian health regulatory agency ANVISA for the importation of Creso's medicinal cannabis product cannaQIX® 50.



Figure 1: cannaQIX® 50



cannaQIX 50® has been developed for patients suffering from chronic pain and, in particular, chronic pain related to neuropathic diseases such as multiple sclerosis, Parkinsons and cancer. The commercialisation of cannaQIX®50 in Brazil follows the product's successful launch in New Zealand last year.

Sales and marketing efforts in Brazil will be supported by Creso's established partnership with SIN Solution, which will also engage in the support of patients' access with regards to regulatory authorities and insurers.

The first focus of marketing, sales and patient support activities will be in the cities of Sao Paulo, Rio de Janeiro, and Curitiba (Parana), which have a combined population of over 22 million people. The main targets are doctors working in the fields of oncology and neurology with an initial estimated addressable market of over 50,000 patients.

Brazil-based SIN Solution is a well-established call centre company that specialises in market-access sales of healthcare products in Brazil and across Latin America. It has direct access to more than 350,000 health professionals and over 200,000 patients.

Creso will import cannaQIX®50 through MedDepot, which is an established Brazilian company based in San Paulo. MedDepot is associated with the SR Group, a North American group with headquarters in Miami dedicated to the worldwide distribution of medicines. MedDepot specialises in the importation of medicines that are not commercialised in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.

cannaQIX 50® differentiates itself from currently available medical cannabis oils on the market by containing a full spectrum cannabis and hemp oil-based CBD combined with vitamins, minerals and capsicum in an innovative proprietary delivery system providing fast absorption and a high bioavailability in the body.

cannaQIX®50 has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso's partner Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG ("Domaco") to the highest Swiss quality with a "Swiss Made" label.

Jorge Wernli, Commercial Director, Creso Pharma said: "We are excited to receive this ANVISA approval for our first medicinal cannabis product for the Brazilian market. We can now provide patients in Brazil with access to the cannaQIX® 50 product line which has additional benefits, particularly bioavailability, compared to currently available medical cannabis oils on the market. The challenge with medical cannabis products is the efficient delivery of the natural full spectrum plant substances to the body – a challenge that we at Creso have managed to overcome."



Alessandra Cesar, Director, SIN Solution said: “Patients’ access to these new medical cannabis products with improved delivery systems will provide greater benefits and lead to a positive health-economic impact on the Brazilian healthcare system. We are excited to be working with Creso on this marketing initiative.”

Ends

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 419 815 386

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About SIN Solution (www.sinsolution.com)

SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.

It has access to more than 350,000 health professionals and over 200,000 direct patient contacts in the region. SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.

About Med Depot Brasil (www.meddepotbrasil.com)

Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines. It is based in Sao Paulo, Brasil. It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.



About Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.